2889-42144-3-PB.pdf (3.35 MB)
Enzastaurin inhibits ABCB1-mediated drug efflux independently of effects on protein kinase C signalling and the cellular p53 status
journal contribution
posted on 2023-06-09, 03:25 authored by Matin Michaelis, Florian Rothweiler, Nadine Löschmann, Mohsen Sharifi, Taravat Ghafourian, Jindrich Cinatl Jr.The PKCß inhibitor enzastaurin was tested in parental neuroblastoma and rhabdomyosarcoma cell lines, their vincristine-resistant sub-lines, primary neuroblastoma cells, ABCB1-transduced, ABCG2-transduced, and p53-depleted cells. Enzastaurin IC50s ranged from 3.3 to 9.5 µM in cell lines and primary cells independently of the ABCB1, ABCG2, or p53 status. Enzastaurin 0.3125 µM interfered with ABCB1-mediated drug transport. PKCa and PKCß may phosphorylate and activate ABCB1 under the control of p53. However, enzastaurin exerted similar effects on ABCB1 in the presence or absence of functional p53. Also, enzastaurin inhibited PKC signalling only in concentrations = 1.25 µM. The investigated cell lines did not express PKCß. PKCa depletion reduced PKC signalling but did not affect ABCB1 activity. Intracellular levels of the fluorescent ABCB1 substrate rhodamine 123 rapidly decreased after wash-out of extracellular enzastaurin, and enzastaurin induced ABCB1 ATPase activity resembling the ABCB1 substrate verapamil. Computational docking experiments detected a direct interaction of enzastaurin and ABCB1. These data suggest that enzastaurin directly interferes with ABCB1 function. Enzastaurin further inhibited ABCG2-mediated drug transport but by a different mechanism since it reduced ABCG2 ATPase activity. These findings are important for the further development of therapies combining enzastaurin with ABC transporter substrates.
History
Publication status
- Published
File Version
- Published version
Journal
OncotargetISSN
1949-2553Publisher
Impact JournalsExternal DOI
Issue
19Volume
6Page range
17605-17620Department affiliated with
- Biochemistry Publications
Full text available
- Yes
Peer reviewed?
- Yes
Legacy Posted Date
2017-12-01First Open Access (FOA) Date
2017-12-01First Compliant Deposit (FCD) Date
2017-12-01Usage metrics
Categories
No categories selectedKeywords
adenosine triphosphatase; breast cancer resistance protein; enzastaurin; multidrug resistance protein 1; protein kinase C; protein kinase C alpha; protein kinase C beta; protein p53; verapamil; vincristineArticle; cell viability; chemosensitization; concentration response; controlled study; drug mechanism; drug protein binding; drug transport; enzyme activity; human; human cell; molecular docking; protein phosphorylation; signal transduction
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC